Project description:Longitudinal single cell RNA-expression analysis of tumor cells along metastatic relapse. AKP mouse tumor organoids (MTOs) were implanted in the caecum and left to metastasize into the liver. Livers were collected at different timepoints post-injection and GFP+ CD45- cells were sorted in 96-well smart-seq plates. Tumor cells were collected from liver with colorectal cancer (CRC) micrometastatic stage disease.
Project description:Longitudinal single cell RNA-expression analysis of tumor cells along the metastatic cascade. AKTP MTOs were implanted in the caecum and left to metastasize into the liver. Mice with different metastatic burden were collected and GFP+ CD45- cells were sorted in 96-well smart-seq plates. Tumor cells were collected at four stages (Primary tumors, micrometastases, small metastases and big metastases) and each Smart-seq2 plate contained cells from all conditions to avoid batch effects. Primary tumor samples were matched with micro, small or big metastases samples.
Project description:The objective of this scRNAseq was to explore the heterogeneity between tumor epithelial CRC cells in our AKTP mouse models. We compared it to human datasets and found that mouse and human CRCs share similar tumor subpopulations.
Project description:This study is part of MD Anderson Cancer Center CRC Moon Shot. We used single cell RNAsequencing (scRNA-seq) to analyze the diversity of CRC.
Project description:The recent development of spatial omics enables single-cell profiling of the transcriptome and the 3D organization of the genome in a spatially resolved manner. A spatial epigenomics method would expand the repertoire of spatial omics tools and accelerate our understanding of the spatial regulation of cellular processes and tissue functions. Here, we developed an imaging approach for spatially resolved profiling of epigenetic modifications in single cells
Project description:A collection of genetically engineered mouse models (GEMM) of colorectal cancer (CRC) were created, and primary tumors from these GEMMs were analyzed. Primary CRC tumors from these GEMMs were genotyped to confirm that they contain the core genetic lesions of interest, including APC, P53, KRAS, and BRAF. Primary tumors from GEMMs with combinations of lesions of interest were analyzed by whole genome expression, and their expression profiles were compared to determine how they segregate. Signatures were then generated from GEMM tumors of interest and compared to human clinical datasets with expression and outcome data. Primary tumors from CRC GEMMs with different combinations of mutant alleles of interested were generated and analyzed. Alleles include mutant forms of APC (A), P53 (P), KRAS (K) and BRAF (B).